Aleglitazar - CAS 475479-34-6
Catalog number: 475479-34-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Aleglitazar is a potent dual agonist of peroxisome proliferator-activated receptor (PPAR) α/γ.
Publictions citing BOC Sciences Products
  • >> More
R1439; RO0728804
1.Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Henry RR1, Buse JB, Wu H, Durrwell L, Mingrino R, Jaekel K, El Azzouzi B, Andjelkovic M, Herz M. Diabetes Obes Metab. 2015 Jun;17(6):560-5. doi: 10.1111/dom.12455. Epub 2015 Apr 8.
AIMS: To evaluate the potential efficacy, safety and tolerability of aleglitazar as monotherapy or add-on therapy to metformin or to a sulphonylurea (either alone or in combination with metformin).
2.Discontinued in 2013: diabetic drugs.
Hedrington MS1, Davis SN. Expert Opin Investig Drugs. 2014 Dec;23(12):1703-11. doi: 10.1517/13543784.2014.964859. Epub 2014 Sep 24.
INTRODUCTION: The increasing prevalence of diabetes, with no cure on the horizon, continues to provide biopharmaceutical companies with an incentive to develop novel therapies and improve existing compounds.
3.Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B1, Samadi N2, Baradaran B1, Rameshknia V3, Shafiei-Irannejad V4, Majidinia M4, Targhaze N5, Zarghami N6. Cell Mol Biol (Noisy-le-grand). 2015 Dec 30;61(8):118-22.
P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in tumor cells is still a main obstacle for the chemotherapeutic treatment of cancers. Therefore, identification of safe and effective MDR reversing compounds with minimal adverse side effects is an important approach in the cancer treatment. Studies show that peroxisome proliferator-activated receptor (PPARs) ligands can inhibit cell growth in many cancers. Here, we investigated the effect of different PPAR agonists include fenofibrate, troglitazone and aleglitazar on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. The effects of doxorubicin (DOX) following treatment with PPAR agonists on cell viability were evaluated using MTT assay and the reversal fold (RF) values. Rhodamine123 (Rh123) assays were used to determine P-gp functioning. P-gp mRNA/protein expression was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot analysis after incubation with troglitazone and aleglitazar.
4.The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
Hanf R1, Millatt LJ1, Cariou B2, Noel B1, Rigou G1, Delataille P1, Daix V1, Hum DW1, Staels B3. Diab Vasc Dis Res. 2014 Nov;11(6):440-7. doi: 10.1177/1479164114548027. Epub 2014 Sep 11.
We report here the efficacy and safety of GFT505, a novel liver-targeted peroxisome proliferator-activated receptor alpha/delta (PPARα/δ) agonist, in the db/db mouse model of diabetes. Mice were treated with vehicle, GFT505, PPARγ agonist rosiglitazone or dual-PPARα/γ agonist aleglitazar for up to 8 weeks. All compounds comparably reduced fasting glycaemia and HbA1c and improved insulin sensitivity. The glucose-lowering effect of GFT505 was associated with decreased hepatic gluconeogenesis, correlating with reduced expression of gluconeogenic genes. In contrast with the PPARγ-activating drugs, treatment with GFT505 did not affect heart weight and did not increase plasma adiponectin concentrations. This absence of cardiac effects of GFT505 was confirmed after 12 months of administration in cynomolgus monkeys, by the absence of echocardiographic and histological findings. Moreover, long-term GFT505 administration to monkeys induced no change in haematological parameters or in bone marrow differential cell counts.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PPAR Products

CAS 475479-34-6 Aleglitazar

(CAS: 475479-34-6)

Aleglitazar is a potent dual agonist of peroxisome proliferator-activated receptor (PPAR) α/γ.

CAS 539813-69-9 PPAR agonist 1

PPAR agonist 1
(CAS: 539813-69-9)

An agonist of PPAR α and PPAR γ

CDDO Imidazolide
(CAS: 443104-02-7)

CDDO Imidozolide is a synthetic triterpenoid as Nrf2 signaling activator with highly active in suppressing cellular proliferation of human leukemia and breast c...

CAS 49562-28-9 Fenofibrate

(CAS: 49562-28-9)

Fenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative.It is used alone or along with statins in the treatment of hypercho...

(CAS: 851528-79-5)

Seladelpar is a selective peroxisome proliferator-activated receptor -δ receptor agonist. Phase II clinical trials for the treatment of Hyperlipidaemia, Hyperli...

CAS 111025-46-8 Pioglitazone

(CAS: 111025-46-8)

Pioglitazone significantly attenuates left ventricular (LV) cavity dilatation and dysfunction by echocardiography as well as LV end-diastolic pressure in mice w...

CAS 22978-25-2 GW9662

(CAS: 22978-25-2)

GW9662 is a potent, irreversible and selective PPARgamma antagonist, which prevented activation of PPARgamma and inhibited growth of human mammary tumour cell ...

CAS 313516-66-4 T0070907

(CAS: 313516-66-4)

T0070907 was identified as a potent and selective PPARgamma antagonist. T0070907 blocked PPARgamma function in both cell-based reporter gene and adipocyte diffe...

CAS 188591-46-0 GSK-3787

(CAS: 188591-46-0)

GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties.

(CAS: 824932-88-9)

Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. It induces resolution of nonalco...

CAS 476436-68-7 Naveglitazar

(CAS: 476436-68-7)

Naveglitazar is a Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist

(CAS: 1168138-37-1)

PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation...

CAS 122320-73-4 Rosiglitazone

(CAS: 122320-73-4)

Rosiglitazone is a potent antihyperglycemic agent and a potent thiazolidinedione insulin sensitizer with IC50 of 12, 4 and 9 nM for rat, 3T3-L1 and human adipoc...

CAS 52214-84-3 Ciprofibrate

(CAS: 52214-84-3)

Ciprofibrate is a peroxisome proliferator-activated receptor agonist.

(CAS: 848259-27-8)

Pemafibrate is a Peroxisome proliferator-activated receptor alpha agonist. It can decrease the secretion of inflammatory markers without affecting cell prolifer...

CAS 50892-23-4 Pirinixic Acid

Pirinixic Acid
(CAS: 50892-23-4)

WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.

(CAS: 1067214-81-6)

GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells.

CAS 79558-09-1 L-165041

(CAS: 79558-09-1)

L-165041 is a cell permeable PPARδ agonist which induces adipocyte differentiation in NIH-PPARδ cells. It displays more than 100-fold selectivity for both mouse...

DG172 dihydrochloride
(CAS: 1361504-77-9)

The dihydrochloride salt form of DG-172, a piperazin drrivative, is a PPARβ/δ inverse agonist that could promote cell differentiation of dendritic induced by GM...

CAS 223132-37-4 Inolitazone

(CAS: 223132-37-4)

Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...

Chemical Structure

CAS 475479-34-6 Aleglitazar

Quick Inquiry

Verification code

Featured Items